Nanoviricides (NV) has announced its first clinical study, a key milestone in the development of its novel and innovative anti-virus therapy, NV-CoV-2. The technology uses a sophisticated large polymer (NV-387) to trap and disrupt viruses in the blood. The therapy aims to reduce the viral load to p
